CAY10499: Precision Inhibitor of Human Hormone Sensitive Lipase in Applied Lipid Metabolism Assays

Principle and Rationale: Targeting Lipid Mobilization with Selectivity

Understanding the dynamic role of hormone sensitive lipase (HSL) and monoglyceride lipase (MGL) in lipid metabolism is foundational for research spanning metabolic disease, steroidogenesis, and immune microenvironments. CAY10499, a crystalline small molecule provided by APExBIO, functions as a selective inhibitor of human hormone sensitive lipase, with an IC₅₀ of 90 nM, and of monoglyceride lipase, with an IC₅₀ of 0.5 ± 0.03 μM (source: product_spec). By targeting these critical enzymes, CAY10499 helps unravel the complexities of fatty acid mobilization, endocannabinoid signaling, and cholesterol ester hydrolysis, providing a robust platform for both basic and translational research.

Step-by-Step Workflow: Enhancing Lipid Metabolism and Immune Cell Assays

Deploying CAY10499 in experimental workflows demands both technical rigor and awareness of its solubility and stability properties. Below is a streamlined protocol for its use in lipid metabolism assays, with a focus on maximizing specificity and reproducibility.

Protocol Parameters

• assay: Lipase activity inhibition in cell lysates | value_with_unit: 200 nM CAY10499, 30-minute pre-incubation at 37°C | applicability: Quantitative inhibition of HSL/MGL in adipocyte or macrophage lysates | rationale: Ensures robust enzyme inhibition prior to substrate addition, matching published IC₅₀ values | source_type: product_spec
• assay: Solubilization for stock solution | value_with_unit: ≥32.4 mg/mL in DMSO | applicability: Preparation of concentrated stocks for serial dilution | rationale: Maximizes working concentration range and minimizes DMSO in final assay volume | source_type: product_spec
• assay: FAAH inhibition in competitive binding | value_with_unit: 76 nM CAY10499, 20-minute incubation | applicability: Control for selectivity in endocannabinoid hydrolysis assays | rationale: Distinguishes HSL/MGL inhibition from off-target FAAH effects | source_type: product_spec
• assay: Long-term storage | value_with_unit: -20°C in desiccated conditions | applicability: Retains compound stability for months | rationale: Prevents degradation and moisture uptake | source_type: product_spec

Key Innovation from the Reference Study

The recent Advanced Science research article spotlights how hepatocellular carcinoma (HCC) cells exploit extracellular vesicle (EV)-transferred ATP-citrate lyase (ACLY) to reprogram monocytes into immunosuppressive tumor-associated macrophages (TAMs). By driving lipogenesis and protein palmitoylation in recipient immune cells, this mechanism amplifies tumor progression and therapeutic resistance. The study’s use of engineered liposomal vesicles to directly modulate monocyte metabolism offers a new paradigm for dissecting lipid-driven immunology. For researchers leveraging CAY10499, this insight translates into practical assay design: by combining HSL/MGL inhibition with EV- or lipidation-centric protocols, one can probe the metabolic crosstalk between tumors and myeloid cells, or test candidate therapies that disrupt lipid-fueled immune suppression.

Comparative Advantages and Advanced Applications

CAY10499 stands apart as both an inhibitor for steroidogenesis research and a lipid metabolism assay reagent, owing to its high selectivity and broad applicability. Unlike non-selective lipase inhibitors, CAY10499 shows minimal displacement of [3H]-CP-55940 from CB1/CB2 cannabinoid receptors, confirming its specificity (source: product_spec). This attribute is crucial for studies where endocannabinoid signaling must be preserved or dissected independently from bulk lipid catabolism. Recent comparative work (article) affirms that CAY10499’s reproducible inhibition of both HSL and MGL enables clear interpretation of lipid turnover in metabolic and immune cell models, while another resource (article) highlights the compound’s utility in deconvoluting lipid signaling from enzyme-specific effects, making it a preferred enzyme inhibitor for fatty acid mobilization studies.

In the context of atherosclerosis research, CAY10499’s inhibition of HSL-mediated foam cell formation aligns with its value as a research tool for atherosclerosis (source: article). Furthermore, targeting monoglyceride lipase with CAY10499 provides a route to modulate 2-arachidonoylglycerol metabolism, relevant for both metabolic and neuroimmune assays.

Workflow Enhancements: Setup and Troubleshooting Tips

• Solubility Management: Dissolve CAY10499 in DMSO to concentrations up to 32.4 mg/mL. If precipitation occurs, gently warm and vortex. Avoid water as a solvent due to insolubility (source: product_spec).
• Assay Interferences: If unexpected background persists, verify DMSO concentration is ≤1% in the final reaction, as higher levels may affect cell viability or enzyme kinetics (workflow_recommendation).
• Stability Assurance: Aliquot stocks and minimize freeze-thaw cycles. For multi-day experiments, prepare fresh working dilutions daily (source: product_spec).
• Control Selection: Include vehicle-only and, where possible, FAAH or non-lipase controls to distinguish on-target effects from off-target interference (workflow_recommendation).
• Assay Specificity: In cell-based models, confirm HSL/MGL pathway engagement with substrate or product-specific readouts (workflow_recommendation).

Integrated Knowledge: Article Interlinks and Research Context

The methodology and insights from the reference study on EV-transferred ACLY provide a mechanistic rationale for using CAY10499 in tandem with lipid-modifying interventions. This approach complements findings from "CAY10499: Precision Lipase Inhibition for Lipid Signaling Research", which explores the compound's selectivity and its implications for dissecting immune-metabolic pathways. In contrast, the workflow-centric strategies detailed in "CAY10499: Reliable Inhibitor of Human Hormone Sensitive Lipase" offer practical advice for optimizing experimental reproducibility and quantitative data analysis. Together, these resources frame CAY10499 as both a mechanistic probe and a robust tool for workflow optimization in advanced lipid research.

Future Outlook: Implications and Next Steps

The intersection of lipid metabolism and immune regulation, as revealed by the reference study, underscores the growing need for enzyme inhibitors that combine selectivity with operational flexibility. CAY10499’s capacity to precisely inhibit HSL and MGL enables researchers to model metabolic-immune crosstalk in disease-relevant settings, such as in the characterization of tumor-associated macrophages or the study of metabolic remodeling in atherosclerosis. As new technologies for extracellular vesicle engineering and lipidomics emerge, integrating CAY10499 into these workflows will further enhance our ability to dissect and therapeutically target lipid-driven disease mechanisms (source: paper).

For detailed reagent information and ordering, visit CAY10499, a potent inhibitor of human hormone sensitive lipase and monoglyceride lipase at APExBIO.